Current efficacy and prospectives of oral direct-acting antiviral drugs to treat chronic hepatitis c

Ching Chu Lo; Mei Tsu Chen; Kuo Chih Huang; Chien Hung Lin; Hsu Sheng Cheng; Yee Tam Liao; Li Wen Hung; Sheng Nan Lu; Chien Hung Chen

doi:10.6314/JIMT.201812_29(6).03

Current efficacy and prospectives of oral direct-acting antiviral drugs to treat chronic hepatitis c

Ching Chu Lo, Mei Tsu Chen, Kuo Chih Huang, Chien Hung Lin, Hsu Sheng Cheng, Yee Tam Liao, Li Wen Hung, Sheng Nan Lu, Chien Hung Chen

Research output: Contribution to journal › Journal Article › peer-review

Abstract

Chronic hepatitis C is one of the main reasons for the high ranking of liver diseases in Taiwan. With the popularization of oral direct-acting antiviral drugs (DAA), DAAs have been reimbursed by the NHI, and achieved per- protocol SVR rate up to 97%. Despite good SVR rate, less than 10% of the entire hepatitis C population in Taiwan are willing to seek treatment, so there is still a great unmet need in prevention of hepatitis C. Under limited resources, we suggest a pilot project by expanding screening and treatment universalization with DAA and expect to eradicate hepatitis C in Taiwan as soon as possible. (J Intern Med Taiwan 2018; 29:364-373).

Original language	English
Pages (from-to)	364-373
Number of pages	10
Journal	Journal of Internal Medicine of Taiwan
Volume	29
Issue number	6
DOIs	https://doi.org/10.6314/JIMT.201812_29(6).03
State	Published - 12 2018
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2018 Society of Internal Medicine of Taiwan. All rights reserved.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.6314/JIMT.201812_29(6).03

Cite this

@article{cf9e7cc98c6b4b919001a5e32a8e89f4,

title = "Current efficacy and prospectives of oral direct-acting antiviral drugs to treat chronic hepatitis c",

abstract = "Chronic hepatitis C is one of the main reasons for the high ranking of liver diseases in Taiwan. With the popularization of oral direct-acting antiviral drugs (DAA), DAAs have been reimbursed by the NHI, and achieved per- protocol SVR rate up to 97%. Despite good SVR rate, less than 10% of the entire hepatitis C population in Taiwan are willing to seek treatment, so there is still a great unmet need in prevention of hepatitis C. Under limited resources, we suggest a pilot project by expanding screening and treatment universalization with DAA and expect to eradicate hepatitis C in Taiwan as soon as possible. (J Intern Med Taiwan 2018; 29:364-373).",

author = "Lo, {Ching Chu} and Chen, {Mei Tsu} and Huang, {Kuo Chih} and Lin, {Chien Hung} and Cheng, {Hsu Sheng} and Liao, {Yee Tam} and Hung, {Li Wen} and Lu, {Sheng Nan} and Chen, {Chien Hung}",

year = "2018",

month = dec,

doi = "10.6314/JIMT.201812_29(6).03",

language = "英语",

volume = "29",

pages = "364--373",

journal = "Journal of Internal Medicine of Taiwan",

issn = "1016-7390",

publisher = "Society of Internal Medicine of Taiwan",

number = "6",

}

TY - JOUR

T1 - Current efficacy and prospectives of oral direct-acting antiviral drugs to treat chronic hepatitis c

AU - Lo, Ching Chu

AU - Chen, Mei Tsu

AU - Huang, Kuo Chih

AU - Lin, Chien Hung

AU - Cheng, Hsu Sheng

AU - Liao, Yee Tam

AU - Hung, Li Wen

AU - Lu, Sheng Nan

AU - Chen, Chien Hung

PY - 2018/12

Y1 - 2018/12

N2 - Chronic hepatitis C is one of the main reasons for the high ranking of liver diseases in Taiwan. With the popularization of oral direct-acting antiviral drugs (DAA), DAAs have been reimbursed by the NHI, and achieved per- protocol SVR rate up to 97%. Despite good SVR rate, less than 10% of the entire hepatitis C population in Taiwan are willing to seek treatment, so there is still a great unmet need in prevention of hepatitis C. Under limited resources, we suggest a pilot project by expanding screening and treatment universalization with DAA and expect to eradicate hepatitis C in Taiwan as soon as possible. (J Intern Med Taiwan 2018; 29:364-373).

AB - Chronic hepatitis C is one of the main reasons for the high ranking of liver diseases in Taiwan. With the popularization of oral direct-acting antiviral drugs (DAA), DAAs have been reimbursed by the NHI, and achieved per- protocol SVR rate up to 97%. Despite good SVR rate, less than 10% of the entire hepatitis C population in Taiwan are willing to seek treatment, so there is still a great unmet need in prevention of hepatitis C. Under limited resources, we suggest a pilot project by expanding screening and treatment universalization with DAA and expect to eradicate hepatitis C in Taiwan as soon as possible. (J Intern Med Taiwan 2018; 29:364-373).

UR - http://www.scopus.com/inward/record.url?scp=85060809755&partnerID=8YFLogxK

U2 - 10.6314/JIMT.201812_29(6).03

DO - 10.6314/JIMT.201812_29(6).03

M3 - 文章

AN - SCOPUS:85060809755

SN - 1016-7390

VL - 29

SP - 364

EP - 373

JO - Journal of Internal Medicine of Taiwan

JF - Journal of Internal Medicine of Taiwan

IS - 6

ER -

Current efficacy and prospectives of oral direct-acting antiviral drugs to treat chronic hepatitis c

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this